Skip to Main Content

And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans. Our agenda is modest, for now. We plan to catch up on our reading, promenade with the official mascot, and putter around the castle. And what about you? This remains a fine time to enjoy the great outdoors. You could boost the economy by getting a jump on holiday shopping. Or you could reach out to someone who may be feeling isolated right now. Well, whatever you do, have a grand time. But be safe — wear a mask. Enjoy, and see you soon. …

After a rocky start, Food and Drug Commissioner Stephen Hahn has won over critics, The Wall Street Journal tell us. The agency’s success in earning the backing of the Trump administration for a rigorous approval process for a Covid-19 vaccine eased fears it was putting politics before science. “He stood up to Trump and he’s doing the right thing with vaccines,” says Eric Topol, director of the Scripps Research Translational Institute.


Humanigen (HGEN), a small company whose stock has more than quadrupled this year because of hopes about its potential treatment for Covid-19, reported that the drug is performing well in a clinical trial and that it has begun a research partnership with Operation Warp Speed, STAT writes. But two experts in clinical trial statistics say they do not think the effectiveness claims are appropriate — and the company should not have any knowledge about the efficacy of the drug in the ongoing study at all.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!